[go: up one dir, main page]

SMT201600365B - Polipeptidi chimerici e loro uso nella decolonizzazione batterica - Google Patents

Polipeptidi chimerici e loro uso nella decolonizzazione batterica

Info

Publication number
SMT201600365B
SMT201600365B SM201600365T SM201600365T SMT201600365B SM T201600365 B SMT201600365 B SM T201600365B SM 201600365 T SM201600365 T SM 201600365T SM 201600365 T SM201600365 T SM 201600365T SM T201600365 B SMT201600365 B SM T201600365B
Authority
SM
San Marino
Prior art keywords
decolonization
bacterial
chemical polypeptides
polypeptides
chemical
Prior art date
Application number
SM201600365T
Other languages
English (en)
Inventor
Holger Grallert
Sonja Leopoldseder
Original Assignee
Hypharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42153758&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600365(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hypharm Gmbh filed Critical Hypharm Gmbh
Publication of SMT201600365B publication Critical patent/SMT201600365B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24075Lysostaphin (3.4.24.75)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SM201600365T 2009-12-23 2016-10-12 Polipeptidi chimerici e loro uso nella decolonizzazione batterica SMT201600365B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09015998A EP2338916A1 (en) 2009-12-23 2009-12-23 Chimeric polypeptides and their use in bacterial decoloniation
PCT/EP2010/007941 WO2011076432A1 (en) 2009-12-23 2010-12-23 Chimeric polypeptides and their use in bacterial decolonization

Publications (1)

Publication Number Publication Date
SMT201600365B true SMT201600365B (it) 2016-11-10

Family

ID=42153758

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600365T SMT201600365B (it) 2009-12-23 2016-10-12 Polipeptidi chimerici e loro uso nella decolonizzazione batterica

Country Status (14)

Country Link
US (4) US9057059B2 (it)
EP (2) EP2338916A1 (it)
CY (1) CY1118331T1 (it)
DK (1) DK2516471T4 (it)
ES (1) ES2597579T5 (it)
HR (1) HRP20161320T4 (it)
HU (1) HUE031164T2 (it)
LT (1) LT2516471T (it)
PL (1) PL2516471T5 (it)
PT (1) PT2516471T (it)
RS (1) RS55230B1 (it)
SI (1) SI2516471T2 (it)
SM (1) SMT201600365B (it)
WO (1) WO2011076432A1 (it)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
WO2013170022A1 (en) * 2012-05-09 2013-11-14 Contrafect Corporation Biofilm prevention, disruption and treatment with bacteriophage lysin
WO2014078373A1 (en) * 2012-11-13 2014-05-22 Iogenetics, Llc Antimicrobial compositions
CN103122347B (zh) * 2013-02-01 2015-04-22 中国科学院武汉病毒研究所 一种杀灭葡萄球菌的裂解酶及其应用
DK3019185T3 (da) * 2013-07-11 2021-02-15 Micreos Human Health Bv Kombinationsbehandling for atopisk dermatitis
EP2904912A1 (en) 2014-02-07 2015-08-12 Hyglos Invest GmbH Novel high pressure method with endolysin for processing of foods
CA2979873A1 (en) 2015-03-12 2016-09-15 Micreos Human Health B.V. Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
CN104805066B (zh) * 2015-05-18 2018-04-24 武汉菲吉乐科生物科技有限公司 一种葡萄球菌裂解酶及其应用
KR20230164221A (ko) 2016-11-18 2023-12-01 뤼산도 아게 스태필로코커스 아우레우스에 대한 신규한 항미생물제
US10256592B1 (en) * 2017-04-27 2019-04-09 Lockheed Martin Corporation Device, system and method with cascaded burst mode laser amplified pumping oscillator signal
EP3873917A4 (en) * 2018-11-02 2022-08-17 The Rockefeller University COMPOSITIONS AND METHODS COMPRISING LYSOCINES AS BIOTECHNICAL ANTIMICROBIAL FOR USE IN TARGETING GRAM-NEGATIVE BACTERIA
BR112021022283A2 (pt) * 2019-05-08 2021-12-28 Phagomed Biopharma Gmbh Novas endolisinas de gardnerella e usos das mesmas
GB201906653D0 (en) * 2019-05-10 2019-06-26 Cc Biotech Ltd Polypeptides for treatment of bacterial infections
EP3771463A1 (en) 2019-07-29 2021-02-03 Ludwig-Maximilians-Universität München Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances
WO2021185948A1 (en) 2020-03-19 2021-09-23 Micreos Human Health B.V. A stabilized protein of interest
WO2024241070A1 (en) 2023-05-22 2024-11-28 L'oreal Cosmetic composition comprising an endolysin and a polyvinyl alcohol
CN121358455A (zh) * 2023-06-02 2026-01-16 莱雅公司 包含衍生自金黄色葡萄球菌噬菌体的内溶素和芳族醇的化妆品组合物
FR3149207A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition cosmétique comprenant une endolysine et un composé de formule (I)
FR3149203A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane
FR3149202A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile.
FR3149209A1 (fr) * 2023-06-02 2024-12-06 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique
FR3149208A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition cosmétique, notamment aqueuse, comprenant une endolysine et un pullulane
FR3149206A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition cosmétique aqueuse comprenant une endolysine et du tréhalose
FR3152395A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et la 4-hydroxyacetophenone
FR3149205A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition cosmétique comprenant une endolysine et un agent de charge organique
FR3149204A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition cosmétique comprenant une endolysine et un tensioactif non ionique comprenant un résidu carbohydrate
FR3152393A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine dérivée d’un phage de Staphylococcus aureus et une charge minérale
FR3152396A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un polyhydroxyalcane
FR3152394A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine et des particules d’aérogel de silice hydrophobe
WO2025093666A1 (en) 2023-11-01 2025-05-08 University Of Copenhagen Treatment of lymphoma
PL449073A1 (pl) * 2024-06-29 2026-01-05 Instytut Medycyny Doświadczalnej I Klinicznej Im. M. Mossakowskiego Polskiej Akademii Nauk Rekombinowane białko o właściwościach przeciwbakteryjnych zawierające aktywną domenę katalityczną CHAP, kompozycje je zawierające, zastosowania oraz sposoby je wykorzystujące

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2255561B (en) 1991-04-20 1995-06-21 Agricultural & Food Res Lysins from bacteriophages
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US7572602B1 (en) * 2004-12-03 2009-08-11 The United States Of America As Represented By The Secretary Of Agriculture Nucleic acid encoding endolysin fusion protein
ES2536852T3 (es) 2006-05-05 2015-05-28 Gangagen, Inc. Actividades antimicrobianas derivadas de fagos
IE20060488A1 (en) 2006-06-29 2008-01-09 Teagasc Agric Food Dev Authori Recombinant staphylococcal phage lysin as an antibacterial agent
US20090130082A1 (en) * 2007-10-18 2009-05-21 Kaplan Jeffrey B Compositions and methods for the treatment and prevention of infections caused by staphylococcus aureus bacteria
WO2010011960A2 (en) 2008-07-24 2010-01-28 The United State Of America, As Represented By The Secretary Of Agriculture Triple acting antimicrobials that are refractory to resistance development
US8383102B2 (en) * 2009-05-21 2013-02-26 The United States Of America As Represented By The Secretary Of Agriculture Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens

Also Published As

Publication number Publication date
SI2516471T1 (sl) 2016-11-30
ES2597579T5 (es) 2021-03-18
US20190381151A1 (en) 2019-12-19
DK2516471T3 (en) 2016-10-17
EP2516471A1 (en) 2012-10-31
US9057059B2 (en) 2015-06-16
EP2516471B2 (en) 2020-05-27
US10022430B2 (en) 2018-07-17
US10342857B2 (en) 2019-07-09
RS55230B1 (sr) 2017-02-28
CY1118331T1 (el) 2017-06-28
US20130004476A1 (en) 2013-01-03
HUE031164T2 (en) 2017-06-28
SI2516471T2 (sl) 2020-07-31
EP2516471B9 (en) 2020-10-28
PT2516471T (pt) 2016-10-20
US20150238577A1 (en) 2015-08-27
US11116824B2 (en) 2021-09-14
HRP20161320T1 (hr) 2016-12-16
ES2597579T3 (es) 2017-01-19
PL2516471T5 (pl) 2020-10-19
LT2516471T (lt) 2016-10-25
EP2338916A1 (en) 2011-06-29
EP2516471B1 (en) 2016-07-13
PL2516471T3 (pl) 2017-01-31
US20180333471A1 (en) 2018-11-22
WO2011076432A1 (en) 2011-06-30
DK2516471T4 (da) 2020-08-03
HRP20161320T4 (hr) 2020-07-10

Similar Documents

Publication Publication Date Title
SMT201600365B (it) Polipeptidi chimerici e loro uso nella decolonizzazione batterica
HRP20190137T1 (hr) Stabilne formulacije polipeptida i njihova uporaba
BR112012013148A2 (pt) formulação farmacêutica e uso
IL254144A0 (en) Methods for reprogramming cells and uses thereof
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BR112013007506A2 (pt) piridinonas/pirazinonas - métodos de criação e de uso
BRPI1007175A2 (pt) Polipeptídeos hidroxifenilpriruvato dioxigenase mutantes e métodos de uso
BRPI1005292A2 (pt) composição de decapagem e uso da composição
BRPI1004349A2 (pt) conjunto de rótulo e uso do mesmo
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
SMT201400164B (it) Morfolino pirimidine e loro uso in terapia
HRP20160737T1 (hr) Anti-her3-protutijela i njihove uporabe
SMT201400146B (it) Morfolino pirimidine e loro uso in terapia
BRPI0914536A2 (pt) tiadiazoliloxifenilamidinas e o uso destas como fungicidas
HUE037061T2 (hu) Specifikusan kötõdõ fehérjék és alkalmazásuk
BR112013010988A2 (pt) composição fluída e uso
HUE045845T2 (hu) Módosított relaxin polipeptidek és felhasználásuk
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI1013432A2 (pt) derivado de indolizina e uso do mesmo para propósitos médicos
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BR112012018329A2 (pt) agentes de coloração e métodos de uso destes
BR112013001423A2 (pt) método, método in vitro, uso e kit útil para realizar o método
BR112012004731A2 (pt) peptídeos derivados de wnt10 e uso dos mesmos
BRPI0907365A2 (pt) Composição antimicrobiana e uso